fCAL turbo on cobas system supported by Roche Diagnostics - Roche Diagnostics Switzerland recently announced the successful collaboration with BÜHLMANN Laboratories AG in bringin the BÜHLMANN fCAL® turbo Calprotectin assay onto their cobas® platform. On the Roche cobas® modular platform the BÜHLMANN fCAL® turbo calprotectin assay can be easily installed and run. In several laboratories on the cobas® c501 modules the assay has been already installed
The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease - BÜHLMANN Quantum Blue® fCAL Citation: Abej, E. et al. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease, Can J Gastroenterol Hepatol. 2016, PMID: 27774443.  Highlight from this publication: “Given the noninvasive nature, quick turnaround of FCAL test, and good correlation with endoscopy in colonic inflammatory bowel diseases as we have shown in
BÜHLMANN announces new Microsite for Kinase Inhibition Assay - BÜHLMANN’s Kinase Inhibition Assay Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3K γ, BTK and SYK Activity Biomarker assays are developed specifically for pharmacokinetic and pharmacodyamic (PK/PD) models during drug discovery and are often used to test efficacy and toxicity. Inhibitors of PI3K, BTK and SYKpathways are a large focus for pharmaceutical companies




Assises Nationales des MICI 2017

Date: 20 January 2017
Place: Paris, France

10èmes Assises Nationales des MICI

SFNLP 2017

Date: 27 – 28 January 2017
Place: Paris, France

21ème Edition Journées de la Société Francophone du Nerf Périphérique


Date: 6 – 9 February 2017
Place: Dubai, U.A.E.

MEDLAB 2017, Dubai International Convention & Exhibition Centre. Visit us at booth #Z6.D38 in New Za’abeel Hall.

ECCO 2017

Date: 15 – 18 February 2017
Place: Barcelona, Spain

Inflammatory Bowel Diseases 2017 – 12th Congress of ECCO. Visit us at booth #10.